 |
4 Diseases |  |
51 Trials |
|
51 Trials |  |
979 News |  |
| «12...234567891011121314» |
- |||| relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
Clinical, Checkpoint inhibition: Wonderful news for our melanoma patients this morning! nivo+relatlimab Phase 3 study met its primary PFS endpoint over nivo alone in first line metastatic melanoma-little added toxicity. Practice changing & a new era for immune checkpoint inhibitors. https://t.co/HRoNqRbKkC (Twitter) - Mar 25, 2021
- | Enrollment change, Trial termination, Combination therapy, Metastases, Immuno-oncology: FRACTION-Lung: An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov) - Mar 22, 2021
P2, N=295, Terminated, Sponsor: Bristol-Myers Squibb
N=504 --> 295 | Active, not recruiting --> Terminated; The standard of care for the patient population changed and we were unable to accrue any longer.
- | relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
Enrollment closed, IO biomarker, Metastases: CA209-587: Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin (clinicaltrials.gov) - Mar 16, 2021
P2, N=31, Active, not recruiting, Sponsor: Salzburger Landeskliniken
N=504 --> 295 | Active, not recruiting --> Terminated; The standard of care for the patient population changed and we were unable to accrue any longer. Recruiting --> Active, not recruiting
- | relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open, Combination therapy, Metastases: T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer (clinicaltrials.gov) - Mar 9, 2021
P1/2, N=18, Recruiting, Sponsor: Inge Marie Svane
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion date, Trial termination, Trial primary completion date, Metastases: Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression (clinicaltrials.gov) - Mar 5, 2021
P2, N=2, Terminated, Sponsor: Elizabeth Davis
Not yet recruiting --> Recruiting Trial completion date: Feb 2024 --> May 2020 | Active, not recruiting --> Terminated | Trial primary completion date: Feb 2023 --> May 2020; Loss of funding
- | relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
Trial completion date, Trial primary completion date, IO biomarker: CA209-906: Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer (clinicaltrials.gov) - Feb 12, 2021
P1, N=25, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Trial completion date: Feb 2024 --> May 2020 | Active, not recruiting --> Terminated | Trial primary completion date: Feb 2023 --> May 2020; Loss of funding Trial completion date: Feb 2023 --> Feb 2024 | Trial primary completion date: Feb 2021 --> Feb 2022
- | relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
Trial completion date: Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC) (clinicaltrials.gov) - Feb 10, 2021
P1, N=20, Not yet recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Trial completion date: Feb 2023 --> Feb 2024 | Trial primary completion date: Feb 2021 --> Feb 2022 Trial completion date: Feb 2026 --> Apr 2025
- | relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment closed, Trial completion date, Trial primary completion date, Checkpoint inhibition, Checkpoint block: Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade (clinicaltrials.gov) - Feb 9, 2021
P1, N=18, Active, not recruiting, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Trial completion date: Feb 2026 --> Apr 2025 Recruiting --> Active, not recruiting | Trial completion date: Jun 2021 --> Jan 2022 | Trial primary completion date: Jun 2021 --> Jan 2022
- | relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion date, Trial primary completion date, Checkpoint inhibition, Checkpoint block, Metastases: Neoadjuvant and Adjuvant Checkpoint Blockade (clinicaltrials.gov) - Feb 5, 2021
P2, N=53, Recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting | Trial completion date: Jun 2021 --> Jan 2022 | Trial primary completion date: Jun 2021 --> Jan 2022 Trial completion date: Aug 2021 --> Dec 2022 | Trial primary completion date: Aug 2021 --> Dec 2022
- | New P1 trial, PD(L)-1 Biomarker: Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma (clinicaltrials.gov) - Jan 5, 2021
P1, N=36, Not yet recruiting, Sponsor: Carlo Contreras
- ||| relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
Enrollment change, Mismatch repair, Metastases: Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor (clinicaltrials.gov) - Dec 21, 2020
P2, N=42, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Trial completion date: Aug 2021 --> Dec 2022 | Trial primary completion date: Aug 2021 --> Dec 2022 N=21 --> 42
- |||| relatlimab (BMS-986016) / BMS, Ono Pharma
Clinical: Demiurge AI-based #cancer #clinicaltrials outcome predictions put to the public test (264_2020): SUCCESS for #relatlimab / NCT03662659 / @Bristol_Myers $BMY (Twitter) - Dec 10, 2020
P2
- || relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
New P1 trial: Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC) (clinicaltrials.gov) - Dec 7, 2020
P1, N=20, Not yet recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- | relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
Trial completion date, Trial primary completion date, Combination therapy, PD(L)-1 Biomarker, IO biomarker, Metastases: Nivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanoma Na (clinicaltrials.gov) - Nov 27, 2020
P2, N=42, Recruiting, Sponsor: John Kirkwood
N=21 --> 42 Trial completion date: Oct 2022 --> Dec 2021 | Trial primary completion date: Oct 2020 --> Dec 2021
- || relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
Enrollment open, Trial completion date, Trial primary completion date, Metastases: CA224-094: Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma (clinicaltrials.gov) - Nov 12, 2020
P2, N=27, Recruiting, Sponsor: Jose Lutzky, MD
Trial completion date: Oct 2022 --> Dec 2021 | Trial primary completion date: Oct 2020 --> Dec 2021 Not yet recruiting --> Recruiting | Trial completion date: Sep 2025 --> Dec 2025 | Trial primary completion date: Sep 2023 --> Dec 2023
- ||||| relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
New P2 trial, Combination therapy, PD(L)-1 Biomarker, Metastases: RELATIVITY-104: A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Nov 9, 2020
P2, N=520, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- | relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P1/2 trial, Combination therapy, Metastases: T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer (clinicaltrials.gov) - Nov 1, 2020
P1/2, N=18, Not yet recruiting, Sponsor: Inge Marie Svane
- relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] A phase II study of nivolumab + BMS-986016 (relatlimab) in patients with metastatic uveal melanoma(UM) (CA224-094) () - Oct 14, 2020 - Abstract #SITC2020SITC_1460;
Correlative studies will evaluate pre- and post-treatment characteristics of T cells in the tumor microenvironment and blood. Results N/A Conclusions N/A Ethics Approval The study was approved by the University of Miami Sylvester Cancer Center PRMC #20200847 Consent N/A
- relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] A phase II study of nivolumab + BMS-986016 (relatlimab) in patients with metastatic uveal melanoma(UM) (CA224-094) () - Oct 14, 2020 - Abstract #SITC2020SITC_725;
Correlative studies will evaluate pre- and post-treatment characteristics of T cells in the tumor microenvironment and blood. Results N/A Conclusions N/A Ethics Approval The study was approved by the University of Miami Sylvester Cancer Center PRMC #20200847 Consent N/A
- | relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion date, Trial primary completion date, Checkpoint inhibition, Checkpoint block, Metastases: Neoadjuvant and Adjuvant Checkpoint Blockade (clinicaltrials.gov) - Oct 12, 2020
P2, N=53, Recruiting, Sponsor: M.D. Anderson Cancer Center
Results N/A Conclusions N/A Ethics Approval The study was approved by the University of Miami Sylvester Cancer Center PRMC #20200847 Consent N/A Trial completion date: Aug 2020 --> Aug 2021 | Trial primary completion date: Aug 2020 --> Aug 2021
- | relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
Trial completion date, Trial primary completion date, Mismatch repair, Metastases: Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor (clinicaltrials.gov) - Oct 7, 2020
P2, N=21, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Trial completion date: Aug 2020 --> Aug 2021 | Trial primary completion date: Aug 2020 --> Aug 2021 Trial completion date: Oct 2022 --> Oct 2023 | Trial primary completion date: Oct 2022 --> Oct 2023
- ||| relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
Biomarker, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, PD(L)-1 Biomarker, Metastases: Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer (clinicaltrials.gov) - Oct 7, 2020
P2, N=96, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Trial completion date: Oct 2022 --> Oct 2023 | Trial primary completion date: Oct 2022 --> Oct 2023 N=64 --> 96 | Trial completion date: Feb 2023 --> Feb 2024 | Trial primary completion date: Feb 2023 --> Feb 2024
- ||||| relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
New P2 trial, Combination therapy, PD(L)-1 Biomarker, IO biomarker, Metastases, Immuno-oncology: RELATIVITY-073: A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors (clinicaltrials.gov) - Sep 27, 2020
P2, N=250, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- || Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion date, Trial primary completion date, Checkpoint inhibition: NICHE: Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer (clinicaltrials.gov) - Sep 18, 2020
P2, N=60, Recruiting, Sponsor: The Netherlands Cancer Institute
N=64 --> 96 | Trial completion date: Feb 2023 --> Feb 2024 | Trial primary completion date: Feb 2023 --> Feb 2024 Trial completion date: Jan 2020 --> Jan 2022 | Trial primary completion date: Jun 2019 --> Jun 2021
- || relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
New P2 trial, Metastases: CA224-094: Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma (clinicaltrials.gov) - Sep 16, 2020
P2, N=27, Not yet recruiting, Sponsor: Jose Lutzky, MD
- Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] Low-Dose Radiation Decreases Cancer-Associated Fibroblasts and May Increase T-Cell Trafficking into Tumors (Poster Hall) - Sep 13, 2020 - Abstract #ASTRO2020ASTRO_1224;
This patient with metastatic melanoma is the first to receive low-dose radiation after progressing on T-cell therapy, showing that this treatment was adequately tolerated and produced an encouraging clinical response. Our preclinical models showed that LD-XRT reduced the numbers of CAFs and modulated the tumor microenvironment in ways that promoted effector T-cell antitumor responses.
- relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] NEOpredict-Lung: A phase II study of neoadjuvant immunotherapy with nivolumab or nivolumab and Relatlimab in patients with primarily resectable, non-small cell lung cancer (Abstract video presentations) - Sep 3, 2020 - Abstract #DGHO2020DGHO_2068;
P2
The study is actively enrolling; first patient first visit was on March 4, 2020. Clinical trial information: NCT04205552.
- relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] NEOpredict-Lung: A phase II study of neoadjuvant immunotherapy with nivolumab or nivolumab and Relatlimab in patients with primarily resectable, non-small cell lung cancer (Abstract video presentations) - Sep 3, 2020 - Abstract #DGHO2020DGHO_1364;
P2
The study is actively enrolling; first patient first visit was on March 4, 2020. Clinical trial information: NCT04205552.
- relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] NEOpredict-Lung: A phase II study of neoadjuvant immunotherapy with nivolumab or nivolumab and Relatlimab in patients with primarily resectable, non-small cell lung cancer (Abstract video presentations) - Sep 3, 2020 - Abstract #DGHO2020DGHO_605;
P2
The study is actively enrolling; first patient first visit was on March 4, 2020. Clinical trial information: NCT04205552.
- || Breyanzi (lisocabtagene maraleucel) / BMS
Trial completion date, Trial primary completion date: PLATFORM: A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (clinicaltrials.gov) - Aug 25, 2020
P1/2, N=100, Recruiting, Sponsor: Celgene
Clinical trial information: NCT04205552. Trial completion date: Apr 2023 --> Aug 2023 | Trial primary completion date: Apr 2023 --> Aug 2023
- ||| relatlimab (BMS-986016) / BMS, Ono Pharma
@JaniceM10 if IMspire150 doesn’t produce sustained PFS benefit, should we use it? Agree with @jasonlukemd that PD-1/ combinations aren’t dead, it’s just that we have room to do better! Hope for relatlimab, bempeg, CpG and others. (Twitter) - Aug 22, 2020
- |||||| relatlimab (BMS-986016) / BMS, Ono Pharma
Biomarker, Clinical, PD(L)-1 Biomarker, IO Biomarker: COMBI-I (BRAF-MEK-PD1; dab-tram-sparta) is NEGATIVE! #melanoma Initially surprised but guess not w KN022/IMspire150. Need to slow down these P1b->P3 trials & find #biomarkers or at least define specific population. What say you relatlimab, bem-peg & TVEC? https://t.co/7ksQ56MSNU (Twitter) - Aug 22, 2020
- || relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
Trial completion date, Trial primary completion date, Combination therapy: A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies (clinicaltrials.gov) - Aug 11, 2020
P1/2, N=109, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial completion date: Apr 2023 --> Aug 2023 | Trial primary completion date: Apr 2023 --> Aug 2023 Trial completion date: May 2020 --> Jan 2021 | Trial primary completion date: May 2020 --> Dec 2020
- || Breyanzi (lisocabtagene maraleucel) / BMS
Trial completion date, Trial primary completion date: PLATFORM: A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (clinicaltrials.gov) - Aug 11, 2020
P1/2, N=100, Recruiting, Sponsor: Celgene
Trial completion date: May 2020 --> Jan 2021 | Trial primary completion date: May 2020 --> Dec 2020 Trial completion date: Aug 2023 --> Apr 2023 | Trial primary completion date: Aug 2023 --> Apr 2023
- || relatlimab (BMS-986016) / BMS, Ono Pharma, Yervoy (ipilimumab) / BMS
Trial primary completion date, Combination therapy, Metastases: A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment (clinicaltrials.gov) - Aug 10, 2020
P1/2, N=260, Recruiting, Sponsor: Bristol-Myers Squibb
Trial completion date: Aug 2023 --> Apr 2023 | Trial primary completion date: Aug 2023 --> Apr 2023 Trial primary completion date: Apr 2021 --> Apr 2023
- || relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
Trial primary completion date, Combination therapy, Metastases: RELATIVITY-020: An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors (clinicaltrials.gov) - Aug 10, 2020
P1/2, N=1500, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Apr 2021 --> Apr 2023 Trial primary completion date: Jan 2021 --> Nov 2021
- || Trial completion date, Trial primary completion date, Combination therapy, Metastases: RELATIVITY-048: An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread (clinicaltrials.gov) - Aug 10, 2020
P1/2, N=230, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Jan 2021 --> Nov 2021 Trial completion date: May 2022 --> Feb 2023 | Trial primary completion date: Apr 2022 --> Feb 2023
- || relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
Enrollment open, Trial completion date, Trial primary completion date, Combination therapy, Metastases: Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Aug 8, 2020
P1, N=45, Recruiting, Sponsor: Bristol-Myers Squibb
Trial completion date: May 2022 --> Feb 2023 | Trial primary completion date: Apr 2022 --> Feb 2023 Active, not recruiting --> Recruiting | Trial completion date: Jul 2020 --> Jul 2022 | Trial primary completion date: Jun 2020 --> Sep 2021
- || Breyanzi (lisocabtagene maraleucel) / BMS
Trial completion date, Trial primary completion date: PLATFORM: A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (clinicaltrials.gov) - Aug 8, 2020
P1/2, N=100, Recruiting, Sponsor: Celgene
Active, not recruiting --> Recruiting | Trial completion date: Jul 2020 --> Jul 2022 | Trial primary completion date: Jun 2020 --> Sep 2021 Trial completion date: Apr 2023 --> Aug 2023| Trial primary completion date: Apr 2023 --> Aug 2023
- |||| relatlimab (BMS-986016) / BMS, Ono Pharma, Yervoy (ipilimumab) / BMS
Enrollment open, Combination therapy, Metastases: A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment (clinicaltrials.gov) - Aug 7, 2020
P1/2, N=260, Recruiting, Sponsor: Bristol-Myers Squibb
Trial completion date: Apr 2023 --> Aug 2023| Trial primary completion date: Apr 2023 --> Aug 2023 Active, not recruiting --> Recruiting
- ||| relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date, Metastases: CONGRATS: Combination of Nivolumab Plus Relatlimab in Patients With Advanced or Metastatic Soft-tissue Sarcoma: a Proof-of-concept Randomized Phase II Study (clinicaltrials.gov) - Aug 7, 2020
P2, N=67, Recruiting, Sponsor: Institut Bergoni
Active, not recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial completion date: Jun 2024 --> Sep 2024 | Initiation date: Nov 2019 --> Feb 2020 | Trial primary completion date: Nov 2021 --> Mar 2022
- || relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
Enrollment open, Combination therapy: A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab (clinicaltrials.gov) - Aug 7, 2020
P1, N=30, Recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting | Trial completion date: Jun 2024 --> Sep 2024 | Initiation date: Nov 2019 --> Feb 2020 | Trial primary completion date: Nov 2021 --> Mar 2022 Active, not recruiting --> Recruiting
- relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] REACTION – a phase Ib pilot study of nivolumab or nivolumab in combination with relatlimab after targeted radiation in patients with advanced esophagogastric cancer (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_2273;
P1/2
Funding: Bristol-Myers Squibb. Clinical trial identification: NCT03610711.
- ||| Empliciti (elotuzumab) / AbbVie, BMS, relatlimab (BMS-986016) / BMS, renvistobart (BMS-986207) / BMS
Enrollment open, Immuno-oncology: Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT (clinicaltrials.gov) - Jul 7, 2020
P1/2, N=104, Recruiting, Sponsor: Multiple Myeloma Research Consortium
Clinical trial identification: NCT03610711. Not yet recruiting --> Recruiting
- | Trial completion date, Combination therapy, Metastases, Immuno-oncology: FRACTION-RCC: A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma (clinicaltrials.gov) - Jun 17, 2020
P2, N=200, Recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Trial completion date: Jan 2022 --> Jan 2023
- || Trial completion date, Trial primary completion date, Combination therapy, Metastases, Immuno-oncology: FRACTION-GC: A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer (clinicaltrials.gov) - Jun 11, 2020
P2, N=600, Recruiting, Sponsor: Bristol-Myers Squibb
Trial completion date: Jan 2022 --> Jan 2023 Trial completion date: Jun 2022 --> Dec 2022 | Trial primary completion date: Jun 2022 --> Nov 2021
- || Opdivo (nivolumab) / BMS
Enrollment closed, Enrollment change, Trial primary completion date, Combination therapy, PD(L)-1 Biomarker: Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18) (clinicaltrials.gov) - May 20, 2020
P1, N=63, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Trial completion date: Jun 2022 --> Dec 2022 | Trial primary completion date: Jun 2022 --> Nov 2021 Recruiting --> Active, not recruiting | N=100 --> 63 | Trial primary completion date: Aug 2020 --> Jan 2021
- | Biomarker, Trial primary completion date, PD(L)-1 Biomarker: ADVISE: An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment (clinicaltrials.gov) - May 18, 2020
P1, N=50, Recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting | N=100 --> 63 | Trial primary completion date: Aug 2020 --> Jan 2021 Trial primary completion date: Apr 2020 --> Mar 2021
- ||| Opdivo (nivolumab) / BMS
Enrollment change, Combination therapy, Monotherapy: CheckMate 358: An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors (clinicaltrials.gov) - May 15, 2020
P1/2, N=584, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Apr 2020 --> Mar 2021 N=1100 --> 584
- || relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
Enrollment closed, Combination therapy, Metastases: Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors (clinicaltrials.gov) - May 4, 2020
P1, N=45, Active, not recruiting, Sponsor: Bristol-Myers Squibb
N=1100 --> 584 Recruiting --> Active, not recruiting